Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
Status:
Completed
Trial end date:
2019-06-10
Target enrollment:
Participant gender:
Summary
The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose
Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device
is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin
aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but
not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is
when used with different insulin delivery settings in the iLet™ in people with type 1
diabetes. Participants will get fast-acting insulin aspart as participants' insulin and use
the iLet™ as participants' insulin pump with a CGM device. Participants' iLet™ will be set to
2 different insulin delivery settings for 7 days on each setting. The setting participants
get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will
have 4 visits and 1 phone contact with the study or staff.